19 results about "Leukemia lymphoma" patented technology

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention provides an FTO (fluorine-doped tin oxide) inhibitor as well as a preparation method and application thereof, and particularly discloses 2-(substituted benzene miscellaneous group) aromatic formic acid as shown in the following general formula (I), derivative compounds of the 2-(substituted benzene miscellaneous group) aromatic formic acid and pharmaceutically acceptable salts, hydrates or solvates of the 2-(substituted benzene miscellaneous group) aromatic formic acid, which can be used as an FTO target inhibitor for treating diseases related to the FTO target. The compound can be used for treating human myelodysplastic syndrome, such as leukemia, lymphoma, myelodysplastic syndrome, obesity, metablic syndrome (MS), type II diabetes (Type 2 diabetes, T2D), Alzheimer's disease, breast cancer, kidney cancer, colorectal cancer, pancreatic cancer, liver cancer, small cell lung cancer, human bone marrow rhabdomyoma, pancreatic cancer, malignant glioblast brain tumor and the like. # imgabs0 #

The invention relates to a hetero (aromatic) ring substituted cyclic diamine compound, preparation thereof and application of the hetero (aromatic) ring substituted cyclic diamine compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is shown as (I). The compound has an obvious growth inhibition effect on tumor cells of leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophagus cancer, glioma, kidney cancer, nasopharynx cancer, liver cancer, stomach cancer, pancreatic cancer and the like. The compound disclosed by the invention has broad-spectrum anti-tumor activity; the compound has a good tumor inhibition effect and a PD-L1 protein degradation effect, and is a PD-L1 immunomodulator.

Antibodies, fragments thereof and fusion proteins that specifically bind to Clec12A, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including leukemia, lymphoma, or myeloma, including, for example, acute myeloid leukemia.

The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I:or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.

The present invention relates to novel antibodies and fragments that bind to the V domain Ig inhibitory factor (VISTA) of T cell activation, and methods of making and using the same. Methods of use include methods of treating cancers, wherein the cancers include leukemia, lymphoma, solid tumors, and melanoma.

Provided in the present invention are a class of FTO inhibitors, a preparation method therefor and the use thereof. Specifically, disclosed in the present invention are a 2-(substituted phenyl hetero) aromatic formate as shown in general formula (I) and a derivative compound thereof, and a pharmaceutically acceptable salt, hydrate or solvate thereof. The compound can be used as an FTO target inhibitor for treating diseases associated with the FTO target, such as leukemia, lymphoma, myelodysplastic syndrome, obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's disease, breast cancer, kidney cancer, colorectal cancer, pancreatic cancer, liver cancer, small cell lung cancer, human bone marrow rhabdomyosarcoma, pancreatic cancer and malignant glioblastoma.

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

The present invention relates to a new vilazodone derivative (3-(4-(4-(2-chloro-6-methoxyphenyl)piperazine-1-yl)butyl)-cyano-indole) and a synthesis method and application thereof. The vilazodone derivative is 3-(4-(4-(2-chloro-6-methoxyphenyl)piperazine-1-yl)butyl)-cyano-indole, and its chemical structure is as follows: The compound has a significant growth inhibitory effect on a variety of human tumor cells and has excellent inhibitory activity on tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, pancreatic cancer, nasopharyngeal cancer, liver cancer, and gastric cancer. The IC50 effective concentration of the compound on tumor cells such as breast cancer, colorectal cancer, lung cancer, glioma, pancreatic cancer, and nasopharyngeal cancer is lower than that of cisplatin. Experiments show that the vilazodone derivative has a broad-spectrum anti-tumor activity and is expected to become a new anti-tumor drug.

The present invention relates to compounds, compounds for use in a method of treatment, in particular in a method for the prevention or treatment of cancer, methods for preparing the compounds and pharmaceutical compositions comprising the compounds. The compounds are particularly useful for treating leukemia, lymphoma and / or solid tumors in Homo sapiens. The compounds are derivatives of cordycepin (3'-deoxyadenosine) with 2' and / or 5'-amino acid ester phosphoramidate moieties.

The application discloses a D-A-D type organic small molecule, nanoparticles containing the same, and a preparation method and application thereof. The D-A-D type organic small molecule and the nanoparticles thereof are particularly suitable for precise photothermal treatment and real-time imaging guidance of hematological malignancies such as leukemia, lymphoma and multiple myeloma. The D-A-D type organic small molecule constructs a D-A-D type conjugated structure, realizes near-infrared absorption red shift to 685 nm through enhancing intramolecular charge transfer (ICT) effect, and promotes non-radiative transition by using high excited state reorganization energy (lambda=1.29eV), with a photothermal conversion efficiency of more than 35%. The small molecule does not contain metal and halogen, has a molecular weight of about 878 Da, and has good biocompatibility and metabolic potential. The small molecule is self-assembled into nanoparticles with a particle size of about 130 nm, and has good colloidal stability and passive targeting ability. Meanwhile, the high molar absorption coefficient and high-efficiency photothermal conversion characteristics of the small molecule endow the small molecule with strong photoacoustic imaging capability, and the small molecule can be used for real-time monitoring of drug distribution and realization of 'diagnosis and treatment integration'.

This invention discloses a predictive model for assessing the risk of severe cytokine release syndrome (SCR) in patients with hematologic malignancies after CAR-T cell therapy. The model includes a nomogram and a prognostic risk scoring formula to assess the risk of SCR after CAR-T cell infusion. The biomarkers are the peripheral blood cytokine concentrations during 24-48 hours after CAR-T cell infusion, including five cytokines: CX3CL1, GZMB, IL4, IL6, and PDGFAA. The nomogram in this invention is the first predictive model established applicable to assessing the risk of SCR in patients with leukemia, lymphoma, and multiple myeloma undergoing CAR-T cell therapy. The model is simple, intuitive, and easy to implement, effectively helping clinicians assess the risk of SCR after CAR-T cell therapy, thus providing theoretical guidance for patient monitoring and treatment.

The application provides a kind of FTO inhibitor and its preparation method and application, specifically, the application discloses 2-(substituted phenyl hetero) aromatic formic acid and its derivative compound and its pharmaceutically acceptable salt, hydrate or solvate as shown in the following general formula (I), which can be used as FTO target point inhibitor for treating diseases related to FTO target point, such as leukemia, lymphoma, myelodysplastic syndrome, obesity, metabolic syndrome (metabolic syndrome, MS), type 2 diabetes (Type 2 diabetes, T2D), Alzheimer's disease, breast cancer, renal cancer, colorectal cancer, pancreatic cancer, liver cancer, small cell lung cancer, human bone marrow transverse muscle cancer, pancreatic cancer, malignant glioblastoma etc.

The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.

The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I:or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.

The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer comprising an EZH2 inhibitor and a METTL3 inhibitor. When co-administered, the EZH2 inhibitor and METTL3 inhibitor based on proteolysis-targeting chimera (PROTAC) technology exhibit a synergistic anticancer effect that is significantly superior to individual treatments, demonstrating that the co-administration can bring about the effects of preventing or treating various cancers such as leukemia, lymphoma, lung cancer, pancreatic cancer, breast cancer, and colorectal cancer.

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

The invention relates to the field of leukemia / lymphoma diagnosis, more specifically to the detection of minimal numbers of leukemia / lymphoma cells in chronic lymphocytic leukemia (CLL) patients after therapy has started. Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in CLL, the reagent composition comprising a panel of at least six antibodies conjugated to a detectable label, the panel comprising antibodies directed against the markers CD180, CD38, CD81, CD19, CD27 and CD5.

The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, comprising a BTK degrader and a METTL3 inhibitor, for which it has been confirmed that when a BTK degrader and a METTL3 inhibitor based on proteolysis-targeting chimera (PROTAC) technology are co-administered, a synergistic effect of exhibiting notable anticancer activity is achieved compared to when same are used alone, and thus a prevention or treatment effect on various cancers such as leukemia, lymphoma, lung cancer, pancreatic cancer, and breast cancer may be created.